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Introduction {#sec005}
============

Multiple sclerosis (MS) is a heterogeneous disease of the central nervous system (CNS) with typical age of disease onset between 28 and 31 years \[[@pone.0210375.ref001]\]. One of the most common symptoms in multiple sclerosis (MS) is fatigue, affecting up to 90% of all MS patients \[[@pone.0210375.ref002]--[@pone.0210375.ref004]\]. Fatigue may have a large impact on the daily life of MS patients and may impair both quality of life and ability to work \[[@pone.0210375.ref002]--[@pone.0210375.ref004]\]. Depression is also a common symptom in MS with a lifetime prevalence of 40--60% \[[@pone.0210375.ref002], [@pone.0210375.ref003], [@pone.0210375.ref005]\]. The pathophysiology of these symptoms in MS is not fully understood \[[@pone.0210375.ref002]--[@pone.0210375.ref004], [@pone.0210375.ref006]--[@pone.0210375.ref008]\].

Structural MRI studies have shown different patterns of cortical thickness in MS patients who have either fatigue, depression or both depression and fatigue, but these cortical underpinnings only explain a proportion of the total variance of the neuropsychiatric symptoms \[[@pone.0210375.ref009]\]. Diverse results are reported concerning the presence and severity of fatigue in relation to structural MRI findings in MS (lesions, normal appearing white matter damage or grey matter damage) \[[@pone.0210375.ref003], [@pone.0210375.ref007], [@pone.0210375.ref010], [@pone.0210375.ref011]\]. Some have reported changes in regional cortico-subcortical pathways such as in the prefrontal cortex, thalamus and basal ganglia in patients with MS-related fatigue, while studies using utilizing whole-brain approaches have mostly been inconclusive \[[@pone.0210375.ref004], [@pone.0210375.ref007], [@pone.0210375.ref008], [@pone.0210375.ref011]\]. Both structural MRI and functional MRI (fMRI) have been applied in many studies with the aim to understand mechanisms responsible for clinical disability, depression, fatigue and cognitive impairment in MS \[[@pone.0210375.ref003], [@pone.0210375.ref007], [@pone.0210375.ref008], [@pone.0210375.ref010]--[@pone.0210375.ref013]\].

Functional connectivity (FC) can be conceptualized as the interaction between two different brain regions. Disconnection caused by white matter damage in MS leads to brain network dysfunction, named a disconnection syndrome \[[@pone.0210375.ref003]\]. Regional damage to the white and grey matter in MS patients is likely to disrupt brain network connectivity within cortical and sub-cortical networks \[[@pone.0210375.ref014]\]. fMRI has made it possible to assess the integration of activity across distant brain regions and has provided insight into functional brain networks.

Resting-state (rs) fMRI in MS has mainly been used to study the intrinsic functional architecture and connectivity of the brain and relation to disease progression and clinical impairment \[[@pone.0210375.ref014], [@pone.0210375.ref015]\]. In particular, rs-fMRI has highlighted the role of the default mode network (DMN) as a critical hub for both integration and flow of information \[[@pone.0210375.ref016]\]. The DMN comprises the precuneus, the posterior cingulate cortex (PCC), the angular gyrus, the medial prefrontal cortex (mPFC) and the inferior parietal regions \[[@pone.0210375.ref003], [@pone.0210375.ref014]\]. The DMN is most active when a person is not focused on a specific task, often referred to as wakeful rest \[[@pone.0210375.ref016]\]. Assuming a role of the DMN in introspection and rumination, DMN changes in MS patients have been proposed to be linked with cognitive dysfunction and depression \[[@pone.0210375.ref016]--[@pone.0210375.ref018]\].

Some fMRI studies have reported cortico-subcortical dysfunction in MS patients with fatigue, also specifically involving fronto-parietal regions and the basal ganglia \[[@pone.0210375.ref003], [@pone.0210375.ref004], [@pone.0210375.ref019], [@pone.0210375.ref020]\]. Another fMRI study reported that fatigue was mainly associated with rs-FC changes of the DMN, although with different components of the DMN uniquely involved \[[@pone.0210375.ref012]\]. A recent rs-fMRI study found that specific thalamo-cortical connections explained different components of fatigue in MS patients \[[@pone.0210375.ref019]\]. Thus, there is evidence of altered DMN connectivity in MS patients with symptoms of both depression and fatigue. Although related, these symptoms do not always co-occur, and little is known about the different patterns of DMN alterations with different symptom burden \[[@pone.0210375.ref009]\]. On this background, we aimed to study the common and differential associations between symptoms of fatigue and depression and DMN connectivity using rs-fMRI in MS.

Materials and methods {#sec006}
=====================

Participants {#sec007}
------------

We included in total 74 MS patients at Oslo University Hospital for a prospective longitudinal study. Some other data from this study have been published earlier \[[@pone.0210375.ref021], [@pone.0210375.ref022]\]. All participants were diagnosed between January 2009 and October 2012 with relapsing-remitting MS (RRMS) according to the revised McDonald Criteria \[[@pone.0210375.ref023]\] and were referred to brain MRI between January 2012 and January 2013. Seven participants did not perform the rs-fMRI sequence, and the remaining 67 participants were used in the current imaging analyses. The time intervals between MRI scans and clinical tests were for all except one patient within 11 days (mean 0.2, median 1, SD 3.0). One patient had to delay MRI and performed the scan two months after testing, but with no clinical relapse in that period. Exclusion criteria included age \< 18 years or \> 50 years, uncertain diagnosis, non-fluency in Norwegian, neurological or psychiatric disease, steroid intake or clinical relapse within the last six weeks, drug abuse, head trauma, pregnancy and previous adverse gadolinium reaction. Two patients were treated with the same selective serotonin reuptake inhibitor at the time of testing for their depressive symptoms. None of the patients received any medical treatment to improve their fatigue. The project was approved by the regional ethical committee of South Eastern Norway (REC ID:2011/1846), and all participants received oral and written information and gave their written informed consent.

All participants completed a comprehensive neurological examination, including expanded disability status scale (EDSS) by a Neurostatus certified medical doctor (<http://www.neurostatus.net/>) and symbol digits modalities test (SDMT) within the same week as their MRI examination. All participants also completed self-reported questionnaires concerning fatigue (Fatigue Severity Scale, FSS) \[[@pone.0210375.ref024]\], with 9 subscores covering the different dimensions of fatigue, and depressive symptoms (Beck Depressive Inventory II, BDI) \[[@pone.0210375.ref025]\] with a total of 21 subscores to encompass various features of depression. FSS mean score ≥ 4 was categorized as clinically significant fatigue, while BDI sum score ≥ 14 was categorized as clinically significant depressive symptoms \[[@pone.0210375.ref025]\].

MRI acquisition {#sec008}
---------------

The participants were scanned using the same 1.5 T scanner (Avanto, Siemens Medical Solutions; Erlangen, Germany) equipped with a 12-channel head coil. For rs-fMRI we used a T~2~\* weighted echo-planar imaging (EPI) sequence (repetition time (TR) = 3000 milliseconds (ms), echo time (TE) = 70 ms, flip angle (FA) = 90°, voxel size = 3.44 x 3.44 x 4 millimetre (mm), field-of-view (FOV) = 220, descending acquisition, GeneRalized Autocalibrating Partial Acquisition (GRAPPA) acceleration factor = 2), 28 transversally oriented slices, no gap, with a scan time of 7 minutes and 30 seconds, yielding 150 volumes. Three dummy volumes were collected to avoid T1 saturation effects. Structural MRI data were collected using a 3-D T1-weighted Magnetization Prepared Rapid Gradient Echo (MP-RAGE) sequence with the following parameters: TR / TE / time to inversion / FA = 2400 ms / 3.61 ms / 1000 ms / 8°, matrix 192 × 192, field of view = 240. Each scan lasted 7 minutes and 42 seconds and consisted of 160 sagittal slices with a voxel size of 1.20 × 1.25 × 1.25 mm.

FLAIR sequence parameters: TR / TE / time to inversion/ FA = 6000 ms / 3.33 ms / 2200 ms / variable T2, matrix 256 × 204, field of view = 260. Each scan lasted 7 min 02 sec and consisted of 176 sagital slices, with a slice thickness of 1 mm and a voxel size of 1.0 × 1.0 × 1.0 mm.

fMRI pre-processing and analysis {#sec009}
--------------------------------

fMRI analysis was performed using FMRI Expert Analysis Tool (FEAT) Version 6.00, from FMRIB's Software Library \[[@pone.0210375.ref026], [@pone.0210375.ref027]\]. Head motion was corrected using MCFLIRT \[[@pone.0210375.ref028]\] before linear trends and low-frequency drifts were removed (high-pass filter of 0.01 Hertz). Image sequences were examined for excessive head motion causing image artefacts. FSL Brain extraction tool \[[@pone.0210375.ref029]\] was used to remove non-brain tissue. Spatial smoothing was performed using a Gaussian kernel filter with a full width at half maximum (FWHM) of 6 mm \[[@pone.0210375.ref030]\]. FMRIB's Nonlinear Image Registration tool (FNIRT) was used to register the participants fMRI volumes to Montreal Neurological Institute (MNI) 152 standard template using the T1-weighted scan as an intermediate, which had the non-brain tissue removed using procedures for automated volumetric segmentation in Freesurfer 5.3 (<http://surfer.nmr.mgh.harvard.edu/>) \[[@pone.0210375.ref031]\].

Single-session independent component analysis (ICA) was performed for all runs using Multivariate Exploratory Linear Optimized Decomposition into Independent Components (MELODIC) \[[@pone.0210375.ref032]\]. The single-session ICA were submitted to FIX \[[@pone.0210375.ref033]\] for automatic classification into signal and noise components, in order to remove noise components from fMRI data. Data cleaning also included correction based on the estimated motion parameters for each run, using linear regression. FIX has been shown to effectively reduce motion induced variability, outperforming methods based on regression of motion parameters or spikes in the dataset \[[@pone.0210375.ref034]\].

The cleaned and MNI-conformed rs-fMRI datasets were submitted to temporal concatenation group independent component analysis (gICA) using MELODIC \[[@pone.0210375.ref032]\] with a model order of 30. These group level spatial components were then used as spatial repressors against the original rs-fMRI datasets to estimate subject-specific components and associated time series (dual regression \[[@pone.0210375.ref035]\]). The second group ICA component, encompassing the regions of the canonical DMN including the PCC, angular gyrus and mPFC, was thresholded at z\>4 and used as a mask for extracting the mean DMN connectivity value from the subject specific dual-regression maps ([Fig 1](#pone.0210375.g001){ref-type="fig"}). The threshold z\>4 (p = 0.00006) was pragmatically chosen based on previous experience.

![Associations between clinical symptoms and DMN connectivity.\
The correlation between adjusted DMN connectivity with the PCA components in A and B, and between adjusted DMN connectivity with FSS and BDI continuous scores in C and D. The grey tones for each subject represent clinical categories in C and D as described and shown in [Table 1](#pone.0210375.t001){ref-type="table"}, and individual subject scores in A and B. (A) Increased PCA1 (high burden of both fatigue and depression) is positively correlated with DMN connectivity. (B) Decreased PCA2 (low burden of fatigue and high burden of depression) is negatively correlated with DMN connectivity. (C) Mean FSS correlated with DMN connectivity. (D) BDI sum scores correlated with DMN connectivity. Shown in E is the DMN component from the group independent component analysis (gICA). The component z-statistic map was thresholded at z\>4. Depicted in three axial slices the posterior cingulate cortex (PCC) and the medial prefrontal cortex (mPFC) are masked out in red and yellow colours bilaterally.](pone.0210375.g001){#pone.0210375.g001}

Brain morphometry {#sec010}
-----------------

Using the T1-weighted scans we performed cortical reconstruction and volumetric segmentation with FreeSurfer 5.3 (<http://surfer.nmr.mgh.harvard.edu/>) \[[@pone.0210375.ref031]\]. Several processing steps, such as skull stripping, Talairach transforms, atlas registration as well as spherical surface maps and parcellations were then initialized to increase reliability and power \[[@pone.0210375.ref036]\].

Manual quality control of the MRI scans from patients was performed by trained research personnel to identify and edit segmentation errors where possible (n = 17 MRI scans). Lesion filling was performed utilizing automatically generated lesion masks from Cascade \[[@pone.0210375.ref037]\] with the lesion filling tool (<https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/lesion_filling>) in FSL \[[@pone.0210375.ref027]\]. The lesion masks were assessed by a trained neuroradiologist and normalized to MNI space using FLIRT \[[@pone.0210375.ref028]\], with the corresponding T1 image as an intermediate. A probabilistic representation of the lesions across all patients is shown in [S1 Fig](#pone.0210375.s001){ref-type="supplementary-material"}. We estimated total brain volume from the Freesurfer output after lesion filling was performed (BrainSegVolNotVent) and extracted mean cortical thickness across the two hemispheres. Lesion volume was measured based the already mentioned lesion masks from Cascade, encompassing lesions in the whole brain.

Statistical analyses {#sec011}
--------------------

We used MATLAB version 9.2 (The MathWorks Inc., Natick, MA, 2017) and R \[[@pone.0210375.ref038]\] (R Core Team, Vienna, 2018) for statistical analyses. BDI and FSS subscores for all participants were submitted to PCA, decomposing the data into orthogonal components. To increase the statistical power of the PCA, we kept the seven MS patients missing fMRI data. The PCA yielded component loading coefficients for each questionnaire as well as component subject scores, resulting in a ranked list of PCA components with their associations to each BDI and FSS subscores ([Fig 2](#pone.0210375.g002){ref-type="fig"}). The subject scores for the two highest ranked PCA components were extracted for further analysis to test for associations with DMN connectivity.

![PCA from FSS and BDI subscores.\
PCA based on 30 clinical subscores (nine FSS and 21 BDI) for all participants. Left: The cumulative and individual explained variance of each PCA of the total variation in the clinical subscores. Right: A heatmap showing the first six PCA factors and their item loading on each component. Yellow and green boxes indicate association with high scores, while the blue boxes indicate association with low scores. The first PCA component (PCA1) captures common variance across BDI and FSS, while the second PCA component (PCA2) captures a pattern of covarying low FSS with high BDI scores.](pone.0210375.g002){#pone.0210375.g002}

Associations between DMN connectivity and clinical PCA scores were investigated using linear models, adjusting for age and sex. To evaluate effect sizes, we calculated Cohen´s f^2^, also taking into account age and sex. For Cohen´s f^2^ test, effect sizes are considered small (\> 0.02), medium (\> 0.15) and large (\> 0.35). For clinical validation and comparison, we also estimated associations between DMN connectivity and the BDI and FSS continuous sum scores using multiple regression, adjusting for age and sex, and compared extreme groups based on conventional clinical thresholds (see above). To account for disability and cognitive impairment we also investigated the associations from the previously mentioned linear models with SDMT and EDSS scores.

Results {#sec012}
=======

Participant demographics and characteristics {#sec013}
--------------------------------------------

[Table 1](#pone.0210375.t001){ref-type="table"} summarizes demographic and clinical characteristics of the 74 included MS patients. The majority of the participants were women (70%), mean age was 35.0 years (range 21--49 years). The majority of the participants received disease modifying treatment (DMT), whereas 20% of the participants were never treated. The participants were included on average 14.1 months after the date of diagnosis and disease duration was on average 73.0 months (range 5--272 months).

10.1371/journal.pone.0210375.t001

###### Demographic and clinical characteristics of the participants.

![](pone.0210375.t001){#pone.0210375.t001g}

  ------------------------------------------------------------------------- ------------------------------
  ***(a) Demographic characteristics***                                     ***Patients (n = 74)***
      Female, n (%)                                                         52 (70)
      Age, mean years (range)                                               35.0 (21--49)
  **Education**                                                              
      Years, mean (range)                                                   14.9 (9--21)
      ≥ 15 years education n (%)                                            51 (69)
  **Working status**                                                         
      Unemployed or 100% sick leave, n (%)                                  7 (9)
      Working (part- og full-time), student or maternity leave, n (%)       67 (91)
  ***(b) Clinical and MRI characteristics***                                ***Patients (n = 74)***
  **Neurological disability**                                                
      EDSS, mean (range)                                                    2.0 (0--6.0)
      Number of total attacks, mean (range)                                 1.8 (0--5)
  **DMT**                                                                    
      No DMT, n (%)                                                         15 (20)
      Active DMTs, n (%)                                                    48 (65)
      Highly active DMTs, n (%)                                             11 (15)
      Months on treatment before study, mean (range)                        9.4 (0--34)
      Months since diagnosis, mean (range)                                  14.1 (1--34)
      Disease duration, mean months (range)                                 73.0 (5--272)
  **Cognitive disability**                                                   
      SDMT, mean (range)                                                    52.4 (30--80)
  **MRI**                                                                    
      Brain volume, mean cm^3^ (SD, range)                                  1134.3 (98.2, 925.3--1356.6)
      Lesion volume, mean cm^3^ (SD, range)                                 8.58 (4.8, 2.5--26.1)
      Lesion load, mean % (SD, range)                                       0.75 (0.39, 0.24--2.18)
      Cortical thickness, mean mm (SD, range)                               2.42 (0.09, 2.17--2.62)
  ***(c) Self-reported questionnaires***                                    ***Patients (n = 74)***
  **FSS**                                                                    
      FSS, mean (standard deviation (SD))                                   4.2 (1.7)
      Clinically significant fatigue (FSS mean ≥ 4), n (%)                  41 (55)
  **BDI**                                                                    
      BDI sum, mean (SD)                                                    9.1 (6.7)
      Clinically significant depressive symptoms (BDI sum ≥ 14), n (%)      23 (31)
  **FSS and BDI status**                                                     
      No fatigue (FSS mean \< 4) and no depression (BDI sum \< 14), n (%)   32 (43)
      Fatigue (FSS mean ≥ 4) and no depression (BDI sum \< 14), n (%)       19 (26)
      No fatigue (FSS mean \< 4) and depression (BDI sum ≥ 14), n (%)       1 (1)
      Fatigue (FSS mean ≥ 4) and depression (BDI sum ≥ 14), n (%)           22 (30)
  ------------------------------------------------------------------------- ------------------------------

EDSS, Expanded Disability Status Scale; DMT, disease modifying treatment; SDMT, symbol digits modalities test; FSS, Fatigue Severity Scale; BDI, Beck Depression Inventory

Fifty-five percent of all participants had clinically significant fatigue based on the FSS mean scores (FSS ≥ 4), and 31% of all participants had clinically significant depressive symptoms based on BDI sum scores (BDI \> 14). There were no significant differences in FSS and BDI scores between patients with and without rs-fMRI. The first PCA component (PCA1), which reflected common variance across depression and fatigue (high FSS and BDI scores), explained 34% of the total variance in all FSS and BDI items ([Fig 2](#pone.0210375.g002){ref-type="fig"}). The second PCA component (PCA2), which reflected a characteristic pattern of low FSS with high BDI scores, explained 10% of the total variance in all FSS and BDI subscores ([Fig 2](#pone.0210375.g002){ref-type="fig"}).

Associations between clinical scores and DMN connectivity {#sec014}
---------------------------------------------------------

Linear models revealed a significant positive correlation between PCA1 and DMN connectivity with small effect size (Cohen's f^2^ = 0.075, t = 2.17, *p* = 0.03), indicating higher DMN connectivity with higher symptom burden. PCA2, which reflected a characteristic pattern of low FSS scores with high BDI scores, showed a significant negative correlation with DMN connectivity with small effect size (Cohen's f^2^ = 0.067, t = -2.1, *p* = 0.04) ([Fig 1](#pone.0210375.g001){ref-type="fig"}). Linear models revealed a significant positive correlation between FSS continuous mean scores correlated with DMN connectivity (t = 3.1, *p* = 0.003), and a non-significant positive association for BDI continuous sum scores correlated with DMN connectivity (t = 0.8, *p* = 0.39).

Confounding effects in the cohort {#sec015}
---------------------------------

### Symbol digits modalities test {#sec016}

SDMT showed no significant association with DMN connectivity (t = 1.7, p = 0.09). The positive association between PCA1 and DMN connectivity remained significant (t = 3.0, p = 0.0045) when including SDMT in the model. The same model revealed a positive association between DMN connectivity and SDMT (t = 2.6, p = 0.011). The association between PCA2 and DMN became non-significant (t = -1.9, p = 0.061) when including SDMT in the model. The same model revealed a non-significant positive association between DMN connectivity and SDMT (t = 1.6, p = 0.12).

### Expanded disability status scale {#sec017}

EDSS showed no significant association with DMN connectivity (t = 0.3, p = 0.77). The positive association between PCA1 and DMN connectivity remained significant (t = 2.2, p = 0.031) when including EDSS in the model. The same model showed a non-significant association between DMN connectivity and EDSS (t = -0.51, p = 0.61). The negative association between PCA2 and DMN connectivity remained significant (t = -2.0, p = 0.049) when including EDSS in the model. The same model revealed a non-significant positive association between DMN connectivity and EDSS (t = 0.25, p = 0.81).

### Disease modifying treatment {#sec018}

DMT level showed a weak negative association with DMN connectivity (t = -1.8, p = 0.07). The positive association between PCA1 and DMN was reduced (t = 1.9, p = 0.06) when including DMT level in the model. The same model showed no association between DMN connectivity and DMT (t = -1.6, p = 0.12). The negative association between PCA2 and DMN connectivity remained significant (t = -2.1, p = 0.035) when including DMT level in the model. The same model revealed a weak negative association between DMN connectivity and DMT level (t = -2.0, p = 0.05).

### Lesion volume {#sec019}

Lesion volume showed no significant association with DMN connectivity (t = -1.1, p = 0.27). The positive association between PCA1 and DMN connectivity remained significant (t = 2.1, p = 0.04) when including lesion volume in the model. The same model showed a non-significant association between DMN connectivity and lesion volume (t = -1.1, p = 0.30). The negative association between PCA2 and DMN connectivity was reduced (t = -1.8, p = 0.07) when including lesion volume in the model. The same model revealed no association between DMN connectivity and lesion volume (t = -0.65, p = 0.52).

### Brain volume {#sec020}

Brain volume showed no significant association with DMN connectivity (t = -0.14, p = 0.89). The positive association between PCA1 and DMN connectivity remained significant (t = 2.2, p = 0.03) when including brain volume in the model. The same model showed no association between DMN connectivity and brain volume (t = 0.57, p = 0.57). The negative association between PCA2 and DMN connectivity remained significant (t = -2.0, p = 0.05) when including brain volume in the model. The same model revealed a weak association between DMN connectivity and brain volume (t = -0.28, p = 0.78).

### Cortical thickness {#sec021}

Mean cortical thickness across the two hemispheres showed no significant association with DMN connectivity (t = 1.1, p = 0.29). The positive association between PCA1 and DMN connectivity remained significant (t = 2.4, p = 0.02) when including cortical thickness in the model. The same model showed no association between DMN connectivity and cortical thickness (t = 1.5, p = 0.15). The negative association between PCA2 and DMN connectivity was reduced (t = -1.8, p = 0.07) when including cortical thickness in the model. The same model revealed no association between DMN connectivity and cortical thickness (t = 0.72, p = 0.47).

### Associations with PCA1, PCA2, FSS and BDI sum scores {#sec022}

Linear models with PCA1 revealed significant associations between brain volume (t = -2.7, p = 0.01), EDSS (t = 3.1, p = 0.003) and SDMT (t = -2.5, p = 0.02), while not between lesion volume (t = -0.3, p = 0.74), DMT (t = -1.3, p = 0.21) and cortical thickness (t = -1.2, p = 0.25).

Linear models with PCA2 showed significant associations between lesion volume (t = 2.0, p = 0.05), but not between brain volume (t = -0.5, p = 0.61), DMT (t = -0.3, p = 0.75), EDSS (t = -0.2, p = 0.82), SDMT (t = -0.7, p = 0.49) or cortical thickness (t = -1.6, p = 0.12).

Linear models with FSS revealed significant associations with EDSS (t = 3.2, p = 0.002), SDMT (t = -2.1, p = 0.04) and brain volume (t = -2.2, p = 0.03), but not for DMT (t = -1.2, p = 0.25), lesion volume (t = -1.1, p = 0.27) and cortical thickness (t = -0.4, p = 0.72).

Linear models with BDI revealed significant associations with EDSS (t = 2.3, p = 0.02), SDMT (t = -2.2, p = 0.03) and brain volume (t = -2.7, p = 0.009), but not for DMT (t = -1.2, p = 0.22), lesion volume (t = 0.79, p = 0.44) and cortical thickness (t = -1.8, p = 0.07).

Discussion {#sec023}
==========

To understand the variability and mechanisms of fatigue and depression is a key clinical question in MS. This study is to our knowledge among the first to study the complex interaction of fatigue and depression in patients with MS by multivariate decomposition analyses of these symptoms in relation to DMN connectivity measured by rs-fMRI.

Fatigue and depression represent common and strong predictors for quality of life in patients with MS, yet the pathophysiological mechanisms of fatigue and depression in MS patients are poorly understood. Converging lines of evidence have suggested associations between different symptoms (such as fatigue, cognitive impairment, depression) and the organization and synchronization of large-scale brain networks as measured by fMRI \[[@pone.0210375.ref003]\]. Here, using multivariate decomposition of symptoms scores and rs-fMRI data we report significant associations between DMN connectivity and both common and unique symptoms of depression and fatigue in patients with MS. The symptoms presenting in MS patients vary between individuals and is assumed to result primarily from demyelination and microscopic CNS tissue damage \[[@pone.0210375.ref003]\]. Structural MRI studies have found diverse regional correlates with different MS symptoms \[[@pone.0210375.ref009]--[@pone.0210375.ref011]\]. Our results show correlation between DMN FC and FSS and BDI scores in MS, which support and further adds to previous knowledge.

One third of the participants in our study had both fatigue and depression, in line with other studies of MS patients \[[@pone.0210375.ref009]\]. It is important to underline, that in this study, as in most MS papers, depressive symptoms are evaluated by self-reported psychometric scales, and no formal diagnosis of depressive mood disorder has been made \[[@pone.0210375.ref005]\]. Some previous studies have excluded MS patients with depressive symptoms when investigating the associations between symptoms of fatigue and FC changes \[[@pone.0210375.ref007], [@pone.0210375.ref011], [@pone.0210375.ref012]\], while a diffusion tensor imaging study analysed MS patients in subgroups based on the presence of depressive symptoms and fatigue \[[@pone.0210375.ref008]\]. Here, we wanted to disentangle the complex interaction between symptoms of depression and fatigue by multivariate decomposition analyses, enabling a novel approach in the study of fatigue and depression in MS.

We found a significant positive correlation between DMN connectivity and the burden of fatigue and depression (PCA1 in [Fig 1](#pone.0210375.g001){ref-type="fig"}). DMN hyperconnectivity has been demonstrated in depression \[[@pone.0210375.ref039]\]. A recent study investigated FC changes in MS patients with depression and suggested a functional link between depression and cognitive impairment \[[@pone.0210375.ref018]\]. A functional link between depression and Alzheimer's disease has also been reported \[[@pone.0210375.ref040]\]. The same study proposed that depression in MS patients is a result of the demyelination and microscopic CNS tissue damage itself, and not a secondary symptom \[[@pone.0210375.ref018]\]. A study on primary and secondary progressive MS patients found associations between cognitive impairment and reduction in resting state connectivity \[[@pone.0210375.ref041]\]. Our findings support the hypothesis that symptoms of depression and fatigue are associated with altered DMN connectivity in MS, possibly influencing the normal function of the DMN as a critical hub of integration and flow of information.

We found that the second PCA component (PCA2) reflecting low burden of fatigue and a high burden of depressive symptoms was negatively correlated with DMN connectivity, indicating that the clinical presentation of fatigue with no depression was associated with DMN hyperconnectivity. DMN hyperconnectivity in fatigue has been demonstrated in a group of breast cancer survivors, where enhanced intrinsic DMN connectivity with the frontal gyrus was associated with persistent fatigue after completed treatment \[[@pone.0210375.ref042]\]. Our results indicate hyperconnectivity in fatigued MS patients unrelated to depression, possibly caused by the inflammation or structural damage in the brain. Our findings of different DMN patterns depending on the symptom burden of fatigue and depression, may reflect the heterogeneity of symptoms in MS patients, as also reported in a recent review \[[@pone.0210375.ref004]\]. It has also been reported that fatigue in MS patients, in the absence of depressive symptoms, may be driven by rs-FC changes in the DMN \[[@pone.0210375.ref012]\]. This study also uncovered that unique components of the DMN was associated with different FC changes. Such regional DMN analyses were beyond the scope of our study.

When adjusting our findings for cognitive impairment, the positive correlation of the first PCA component with DMN connectivity increased while the negative correlation with the second PCA component were slightly decreased. Disability did not have a confounding effect on the correlation between the PCA components and DMN connectivity. Yet we found a significant positive correlation between both BDI and FSS and EDSS, indicating higher disability with higher symptoms of fatigue and depression. Patients with more effective DMTs showed a trend towards decreased symptom burden of fatigue and depression. Adjusting our findings for DMT level weakened our results with PCA1 and DMN connectivity, while the results between PCA2 and DMN connectivity remained significant. Furthermore, adjusting for cognitive impairment seemed to only strengthen our results, while when adjusting for disability our results remained the same. Including whole-brain volume and cortical thickness, which are sensitive indices of brain morphometry, in the analyses did not affect the correlations between the PCA components and DMN connectivity. Lower brain volume was associated with higher scores of both FSS and BDI. When we controlled for lesion volume in our analyses between the PCA components and DMN connectivity, the second PCA component was reduced, while the first PCA component remained significant. Lesion volume was not associated with neither FSS or BDI scores.

Our sample size is modest, but the participants were very thoroughly characterized and comprise a relatively homogenous group in terms of age, cognitive and physical disability, disease duration, education and clinical course. Concerning fatigue, the participants in our study scored a mean of 4.2 for FSS, which is lower than reported in some larger studies \[[@pone.0210375.ref043]\]. However, the FSS scores for the participants included in this study were in line with a recent Norwegian MS study \[[@pone.0210375.ref006]\]. Fatigue may impair the quality of life and contribute to the establishment and maintenance of depressive symptoms \[[@pone.0210375.ref004]\]. The mean BDI sum score in our dataset was 9.1, which is lower than reported in some studies \[[@pone.0210375.ref005]\], but comparable with a Swedish study \[[@pone.0210375.ref044]\]. Possible reasons for the relatively low BDI sum score in our sample include the low age, newly diagnosed RRMS, short disease duration and few brain lesions in our MS patients \[[@pone.0210375.ref021]\].

Adjusting our results for whole-brain volume, cortical thickness, DMT level, lesion volume, SDMT or EDSS did not alter our observed associations significantly. A more detailed analysis of structural MRI and rs-fMRI data could give further insights into the pathophysiology of depression and fatigue in MS. The associations between the two most prominent PCA components and DMN connectivity identified by rs-fMRI in our study suggest separate underlying alterations in the functional connectome. Previous studies assessing cortical morphometry in an overlapping patient sample reported regional associations between cortical surface areas and several clinical manifestations, where the most prominent structural association were smaller cortical surface area and volume significantly associated with depressive symptoms \[[@pone.0210375.ref021]\].

In addition to our modest sample size, other limitations should be considered when interpreting our results. We did not include lesion filling as part of the fMRI analysis pipeline, but have included both lesion volume and brain volume (after lesion filling) in our analyses to account for confounding effects. In MS patients, permanent damage affects the white matter of the CNS and can cause disconnection syndromes \[[@pone.0210375.ref003]\]. The FC and large-scale networks depend on structural connections, and inter-individual variability in DMN connectivity, and its association with clinical traits, might be mediated by degree of demyelination, atrophy of both the grey and white matter and microscopic CNS damage \[[@pone.0210375.ref017]\]. The lack of healthy controls in our study does not allow us to test for specificity, i.e. to which degree any associations between brain connectivity and clinical symptoms generalize to other groups. Yet, our results only focus on the DMN connectivity changes in relation to neuropsychiatric symptoms within the MS group. Future studies are needed to test if our results can be generalized to other populations.

Conclusion {#sec024}
==========

In conclusion, multivariate decomposition of FSS and BDI symptom data supported that the clinical manifestations of fatigue and depression in patients with MS reflect both overlapping and unique variability in the FSS and BDI subscores. The observed differential correlations between symptoms of fatigue and depression and DMN connectivity underline the heterogeneity and complexity of fatigue and depression in MS. Our analyses revealed that high burden of both fatigue and depression was associated with DMN hyperconnectivity, while we also found hyperconnectivity in DMN to be associated with high burden of fatigue in absence of depression. Effect sizes were in general relatively small, and further investigations into the mechanisms of fatigue and depression in MS are warranted. Multivariate decomposition analyses of MS symptoms in relation to default mode network (DMN) connectivity measured by resting-state-fMRI (rs-fMRI) is a promising method to pursue these questions.
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